NxStage System One: The only portable hemodialysis system FDA-cleared

January 21, 2016
00:0000:00


Jeff Burbank, CEO of NX STAGE Medical, a medical device company that develops, manufactures and markets systems for the treatment of end-stage renal disease, acute kidney failure and fluid overload joins eHealth Radio and the Health Care, Health News, Kidney Health and Technology Channels.


Listen to interview with host Eric Michaels & guest Jeff Burbank discuss the following:

  • Can you please us about your company NX Stage Medical and what exactly your company does?
  • Can you discuss the NxStage System One, which is the only “portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis.
  • What difference does this product make in people’s lives?
  • How has the Affordable Health Act, Obamacare, impacted your business and insurance coverage of your product to your customers?
  • Your product is available around the world. Are there certain parts of the world where your products are used more than other parts of the world when it comes to the nx stage system one?
  • I saw that that 6 years after the earthquake in Haiti, the NxStage System One is still be used there to help folks suffering from acute kidney injury. Can you talk about that.
  • I read recently that your publically traded company is doing well on the stock exchange, can you talk a about what your company’s prospects are in 2016 and the future and where you see your industry moving toward the future.
  • Looking at your biography, I saw that during your career you had been an inventor on over 50 U.S. patents for medical devices. That’s pretty impressive. How did you get into this field and become so proficient and successful in the medical devices industry?


Duration: 10:26


Jeff Burbank is NxStage’s Founder, Chief Executive Officer, and is a member of its Board of Directors. Jeff has over 20 years of in-depth management experience with companies developing, marketing and manufacturing products for End Stage Renal Disease patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, and the acquisition of Medisystems.


Prior to founding NxStage, he co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and CEO, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices.


Jeff received his BS in Industrial Engineering from Lehigh University.


About NxStage Medical


NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.


About NxStage Kidney Care


NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), is innovating a dialysis care model that is intended to support and encourage patient centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients.



Website: www.nxstage.com

Nephrology, a branch of medical science that deals with diseases of the kidneys with Dr. Marc Weinberg

December 2, 2013
00:0000:00


Dr. Marc Weinberg who is Board certified in Internal Medicine and Nephrology (branch of medical science that deals with diseases of the kidneys) joins eHealth Radio and the Kidney Health Channel. He is also Clinical Professor of Medicine at Boston University School of Medicine, and Clinical Associate Professor of Medicine at Brown University Division of Biology and Medicine.


This episode is brought The Expert Institute where you can connect with a local expert within 24 hours by simply visiting TheExpertInstitute.com.


playpodcast.png


Listen to interview with host Eric Michaels & guest Dr. Marc Weinberg discuss the following:

  • Can you tell us about your background, your education and how you decided to enter the field of Nephrology?
  • What is a typical work day like for you?
  • How have some of the common procedures in the field of nephrology evolved since you first became a doctor?
  • Can you discuss any cutting edge techniques that are surfacing?

Duration: 25:34


Dr. Weinberg holds an M.D. degree from Boston University School of Medicine. He was an intern in Internal Medicine at Georgetown University Medical Center, completed a residency in Internal Medicine in the Tufts- New England Medical Center, and a fellowship in Nephrology at Boston University Medical Center.


Dr. Weinberg is Board certified in Internal Medicine and Nephrology.


After serving a career in academic medicine and research in the basic sciences, he was founder of Hypertension & Nephrology, Inc., where he was managing partner since 1986.  He served as Chief Clinical Operating Officer and national Director of Clinical Research for DSI Renal, Inc.


He is Clinical Professor of Medicine at Boston University School of Medicine, and Clinical Associate Professor of Medicine at Brown University Division of Biology and Medicine.


Dr. Weinberg is an expert in the Kallikrein-Kininogen-Kinin System which plays an important role in the regulation of blood pressure and tissue blood flow, salt and water balance, and atherosclerosis.  Dr. Weinberg was the first investigator to publish the use of supramaximal doses of new antihypertensive agents (Angiotensin Receptor Blockers) to reduce proteinuria, as a treatment to preserve kidney function in subjects with protein leakage in the kidney.  His theories have been confirmed internationally by Multicenter prospective trials in the USA and Canada, as well as investigations in Eastern, Western Europe and Japan.


He has lectured internationally in countries such as India, Japan, and Israel, throughout Eastern and Western Europe, and North America.  He serves as Chief of Nephrology at the Roger Williams Medical Center, a Boston University Affiliated Hospital, in Providence, RI.  For nearly fifteen years, he served on the Board of Directors of Blue Cross Blue Shield of Rhode Island, and was Vice Chairman of the Board of Directors and Chairman of the PPAC Committee most recently until his retirement in May, 2006.  He is a past president of the American Heart Association, Rhode Island Affiliate, and of the National Kidney Foundation, Rhode Island affiliate. Dr Weinberg is a Fellow of the American College of Physicians, American Society of Nephrology and American Heart Association.


As Principal Investigator of numerous clinical trials for drugs related to the treatment of Hypertension, Hyperlipidemia, Diabetes, Renal bone disease and anemia, he has almost 100 publications. In 2004, Dr. Weinberg was Inducted into the Collegium and Academy of Distinguished Alumni of the Boston University College and Graduate School of Arts and Sciences.


Currently, Dr. Weinberg developed a Vascular Biology Disease Prevention Program focusing on Reduction of Urinary Proteinuria and Regression of Aortic Aneurysms using maximal blockade of the Renin Angiotensin System with supramaximal doses of Angiotensin Receptor Blockers.


Furthermore, he is Chief of a Heart Attack, Stroke and Diabetes Prevention Method as a novel technique to thwart vascular end organ diseases utilizing investigation of genetics, inflammatory plasma mediators, lipid electrophoresis for particle size and density analysis, and insulin resistance.  His therapeutic modalities span innovative applications of combination pharmacologic and pulse electromagnetic therapies.


Lastly, because of his interest and commitment in the research and development of biochemical and immunological systems which play a role in regulation of blood pressure, vascular inflammation, peripheral vascular and kidney diseases, he joined CellHealth Institute (also Life Sciences Institute) of Montclair, New Jersey and Costa Rica as a Clinical Support Officer. The focus of this start up Biotechnology company is to develop optimal practices in Anti-Aging Medicine and Age Management solutions for physicians. Aging and regenerative medicine is a logical progression of Dr Weinberg’s vascular disease prevention program, adding bio technology for Improving DNA repair, decreasing DNA damage and utilizing stem cell therapy for chronic diseases.


Links: www.marcweinbergmd.com